Revisiting pharmacological concepts and quantitative techniques where nonlinearity and variability are critical
重新审视非线性和可变性至关重要的药理学概念和定量技术
基本信息
- 批准号:RGPIN-2016-05058
- 负责人:
- 金额:$ 1.31万
- 依托单位:
- 依托单位国家:加拿大
- 项目类别:Discovery Grants Program - Individual
- 财政年份:2016
- 资助国家:加拿大
- 起止时间:2016-01-01 至 2017-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Variability and nonlinearity are the two main factors that determine the drug fate in a complex biological system. Because of the paucity of measuring and computing techniques, the community of clinical pharmacology has long been restricted to linear deterministic or simple summary statistical methodologies. However, nowadays drug discovery provides strong evidence for the decisive roles of these two factors in drug kinetics and dynamics. Ignoring variability and nonlinearity when developing drug mathematical models, has been proved to be one reason producing biased predictions out of observed ranges of targeted phenomena. This situation has been changed with the introduction of the population pharmacokinetics/pharmacodynamics modeling approach (Nonlinear Mixed Effect Models) more than two decades ago. With the intention to describe the evolution of drug plasma concentrations and therapeutic effects in a patient population, this new approach successfully introduced different levels of variability within the previously deterministic context defined with ordinary differential equations, and set up the context for the quantitative era of pharmacology, where mathematics are gaining more ground and mathematicians becoming one of the principal actors.
Facing this reality, many pharmacological concepts and methods developed using linear and deterministic principles should be revisited and mathematically revised taking into account the drug related nonlinearity and variability. With the identified three axis, nonlinearity in drug pharmacokinetics, variability in drug intake and therapeutic outcomes, and improvement of drug evaluation issues in the context of variability, the current research program will help to intensify this quantitative trends of pharmacology where mathematics is in the central position but also benefits from new raised problematics. The contribution of the current NSERC discovery grant will be used to investigate various aspects in this direction.
在复杂的生物系统中,可变性和非线性是决定药物命运的两个主要因素。由于缺乏测量和计算技术,临床药理学社区长期以来一直局限于线性确定性或简单的汇总统计方法。然而,目前的药物发现为这两个因素在药物动力学和动力学中的决定性作用提供了强有力的证据。在开发药物数学模型时忽略可变性和非线性,已被证明是产生偏离目标现象观察范围的有偏差预测的原因之一。二十多年前,随着群体药代动力学/药效学建模方法(非线性混合效应模型)的引入,这种情况得到了改变。为了描述患者群体中药物血浆浓度和治疗效果的演变,这种新方法成功地在以前由常微分方程定义的确定性环境中引入了不同水平的可变性,并为药理学的定量时代奠定了基础,在这个时代,数学正在获得更多的基础,数学家成为主要参与者之一。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Li, Jun其他文献
Novel 2-(benzo[d]thiazol-2-yl)-1-(3-methyl-5-substituted-phenyl-4,5-dihydropyr azol-1-yl)ethanone Derivatives: Synthesis and Antibacterial Activity
新型2-(苯并[d]噻唑-2-基)-1-(3-甲基-5-取代-苯基-4,5-二氢吡唑-1-基)乙酮衍生物:合成和抗菌活性
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
Pan, Chun-Xiu;Li, Jun;Liu, Xin-Hua - 通讯作者:
Liu, Xin-Hua
An association analysis between PRL genotype and milk production traits in Italian Mediterranean river buffalo
- DOI:
10.1017/s0022029917000693 - 发表时间:
2017-11-01 - 期刊:
- 影响因子:2.1
- 作者:
Li, Jun;Liang, Aixin;Yang, LiGuo - 通讯作者:
Yang, LiGuo
C698R mutation in Lrsam1 gene impairs nerve regeneration in a CMT2P mouse model.
- DOI:
10.1038/s41598-022-15902-3 - 发表时间:
2022-07-16 - 期刊:
- 影响因子:4.6
- 作者:
Moiseev, Daniel;Wazir, Zafar;Liu, Donghao;Li, Jun;Hu, Bo - 通讯作者:
Hu, Bo
Cryptolepine derivative-6h inhibits liver fibrosis in TGF-β1-induced HSC-T6 cells by targeting the Shh pathway
- DOI:
10.1139/cjpp-2016-0157 - 发表时间:
2016-09-01 - 期刊:
- 影响因子:2.1
- 作者:
He, Ying-Hua;Li, Zeng;Li, Jun - 通讯作者:
Li, Jun
High-Resolution Metagenomics of Human Gut Microbiota Generated by Nanopore and Illumina Hybrid Metagenome Assembly.
- DOI:
10.3389/fmicb.2022.801587 - 发表时间:
2022 - 期刊:
- 影响因子:5.2
- 作者:
Ye, Lianwei;Dong, Ning;Xiong, Wenguang;Li, Jun;Li, Runsheng;Heng, Heng;Chan, Edward Wai Chi;Chen, Sheng - 通讯作者:
Chen, Sheng
Li, Jun的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Li, Jun', 18)}}的其他基金
Revisiting pharmacological concepts and quantitative techniques where nonlinearity and variability are critical
重新审视非线性和可变性至关重要的药理学概念和定量技术
- 批准号:
RGPIN-2016-05058 - 财政年份:2019
- 资助金额:
$ 1.31万 - 项目类别:
Discovery Grants Program - Individual
Revisiting pharmacological concepts and quantitative techniques where nonlinearity and variability are critical
重新审视非线性和可变性至关重要的药理学概念和定量技术
- 批准号:
RGPIN-2016-05058 - 财政年份:2018
- 资助金额:
$ 1.31万 - 项目类别:
Discovery Grants Program - Individual
Rapid transport through robust nanostructures for CO2 electroreduction
通过坚固的纳米结构快速传输二氧化碳电还原
- 批准号:
517727-2017 - 财政年份:2018
- 资助金额:
$ 1.31万 - 项目类别:
Banting Postdoctoral Fellowships Tri-council
Rapid transport through robust nanostructures for CO2 electroreduction
通过坚固的纳米结构快速传输二氧化碳电还原
- 批准号:
517727-2017 - 财政年份:2017
- 资助金额:
$ 1.31万 - 项目类别:
Banting Postdoctoral Fellowships Tri-council
Revisiting pharmacological concepts and quantitative techniques where nonlinearity and variability are critical
重新审视非线性和可变性至关重要的药理学概念和定量技术
- 批准号:
RGPIN-2016-05058 - 财政年份:2017
- 资助金额:
$ 1.31万 - 项目类别:
Discovery Grants Program - Individual
Development of human iPSC reprogramming proteins
人类 iPSC 重编程蛋白的开发
- 批准号:
403158-2010 - 财政年份:2012
- 资助金额:
$ 1.31万 - 项目类别:
Industrial R&D Fellowships (IRDF)
Development of human iPSC reprogramming proteins
人类 iPSC 重编程蛋白的开发
- 批准号:
403158-2010 - 财政年份:2011
- 资助金额:
$ 1.31万 - 项目类别:
Industrial R&D Fellowships (IRDF)
Development of human iPSC reprogramming proteins
人类 iPSC 重编程蛋白的开发
- 批准号:
403158-2010 - 财政年份:2010
- 资助金额:
$ 1.31万 - 项目类别:
Industrial R&D Fellowships (IRDF)
Generation and evaluation of acetylation-specific ING 1 b antibody
乙酰化特异性 ING 1 b 抗体的生成和评估
- 批准号:
342695-2006 - 财政年份:2009
- 资助金额:
$ 1.31万 - 项目类别:
Industrial Postgraduate Scholarships
Generation and evaluation of acetylation-specific ING 1 b antibody
乙酰化特异性 ING 1 b 抗体的生成和评估
- 批准号:
342695-2006 - 财政年份:2008
- 资助金额:
$ 1.31万 - 项目类别:
Industrial Postgraduate Scholarships
相似海外基金
EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort
EPIPHANy(癌症患者抗凝药理相互作用的评估)计划 - 前列腺癌队列
- 批准号:
479295 - 财政年份:2023
- 资助金额:
$ 1.31万 - 项目类别:
Operating Grants
Genetic, environmental, and pharmacological determinants of telomere attrition rates: Implications for the prevention of age-related multimorbidity
端粒损耗率的遗传、环境和药理学决定因素:对预防与年龄相关的多发病的影响
- 批准号:
MR/W028018/1 - 财政年份:2023
- 资助金额:
$ 1.31万 - 项目类别:
Research Grant
MICA: A platform to support the pharmacological targeting of Nrf2 in humans
MICA:支持人类 Nrf2 药理学靶向的平台
- 批准号:
MR/X007413/1 - 财政年份:2023
- 资助金额:
$ 1.31万 - 项目类别:
Fellowship
Center of Research Translation on Osteoporosis Bone Anabolic Therapies
骨质疏松症骨合成代谢疗法研究转化中心
- 批准号:
10404412 - 财政年份:2023
- 资助金额:
$ 1.31万 - 项目类别:
Assessing and Improving the Durability of Compensatory Cognitive Training for Older Veterans (AID-CCT)
评估和提高老年退伍军人补偿性认知训练的持久性 (AID-CCT)
- 批准号:
10636523 - 财政年份:2023
- 资助金额:
$ 1.31万 - 项目类别:
The Influence of Habitual Physical Activity and Diet in the Development of Sarcopenia Among Older Adults With HIV
习惯性体力活动和饮食对老年艾滋病毒感染者肌肉减少症发展的影响
- 批准号:
10699259 - 财政年份:2023
- 资助金额:
$ 1.31万 - 项目类别:
Integrating Tailored Postoperative Opioid Tapering and Pain Management Support for Patients on Long-Term Opioid Use Presenting for Spine Surgery (MIRHIQL)
为脊柱手术中长期使用阿片类药物的患者整合定制的术后阿片类药物逐渐减量和疼痛管理支持 (MIRHIQL)
- 批准号:
10722943 - 财政年份:2023
- 资助金额:
$ 1.31万 - 项目类别:
Pharmacological rescue of tooth eruption disorders
牙萌出障碍的药理学救援
- 批准号:
10737289 - 财政年份:2023
- 资助金额:
$ 1.31万 - 项目类别: